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Background: Due partly to physicians’ unawareness, many adults with Pompe disease are diagnosed with great
delay. Besides, it is not well known which factors influence the rate of disease progression, and thus disease
outcome. We delineated the specific clinical features of Pompe disease in adults, and mapped out the distribution
and severity of muscle weakness, and the sequence of involvement of the individual muscle groups. Furthermore,
we defined the natural disease course and identified prognostic factors for disease progression.
Methods: We conducted a single-center, prospective, observational study. Muscle strength (manual muscle
testing, and hand-held dynamometry), muscle function (quick motor function test), and pulmonary function
(forced vital capacity in sitting and supine positions) were assessed every 3–6 months and analyzed using
repeated-measures ANOVA.
Results: Between October 2004 and August 2009, 94 patients aged between 25 and 75 years were included in the
study. Although skeletal muscle weakness was typically distributed in a limb-girdle pattern, many patients had
unfamiliar features such as ptosis (23%), bulbar weakness (28%), and scapular winging (33%). During follow-up
(average 1.6 years, range 0.5-4.2 years), skeletal muscle strength deteriorated significantly (mean declines of −1.3%
point/year for manual muscle testing and of −2.6% points/year for hand-held dynamometry; both p<0.001). Longer
disease duration (>15 years) and pulmonary involvement (forced vital capacity in sitting position <80%) at study
entry predicted faster decline. On average, forced vital capacity in supine position deteriorated by 1.3% points per
year (p=0.02). Decline in pulmonary function was consistent across subgroups. Ten percent of patients declined
unexpectedly fast.
Conclusions: Recognizing patterns of common and less familiar characteristics in adults with Pompe disease
facilitates timely diagnosis. Longer disease duration and reduced pulmonary function stand out as predictors of
rapid disease progression, and aid in deciding whether to initiate enzyme replacement therapy, or when.
Keywords: Acid α-glucosidase, Glycogen storage disease type II, OMIM number 232300, Lysosomal storage
disorder, Disease progression, Natural course, Prognostic factors* Correspondence: n.beek@erasmusmc.nl
1Department of Neurology, Center for Lysosomal and Metabolic Diseases,
Erasmus MC University Medical Center, ’s-Gravendijkwal 230, 3015 CE,
Rotterdam, the Netherlands
2Department of Pediatrics, Center for Lysosomal and Metabolic Diseases,
Erasmus MC – Sophia Children’s Hospital, University Medical Center,
Rotterdam, the Netherlands
Full list of author information is available at the end of the article
© 2012 van der Beek et al.; licensee BioMed C
Creative Commons Attribution License (http:/
distribution, and reproduction in any mediumentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
van der Beek et al. Orphanet Journal of Rare Diseases 2012, 7:88 Page 2 of 13
http://www.ojrd.com/content/7/1/88Background
Pompe disease is a rare autosomal recessive metabolic
disorder, whereby mutations in the GAA gene lead to
partial or total absence of the lysosomal enzyme acid
α-glucosidase. The disease presents as a spectrum of
phenotypes, ranging from a rapidly fatal phenotype in
infants [1] to slower progressive phenotypes in older
children and adults. [2,3] Many adults with Pompe dis-
ease are diagnosed late in life, when they are already in
an advanced stage of the disease. While this may be due
to clinicians’ unawareness, it may also be explained by
similarities in clinical presentation with other ‘limb-
girdle’ diseases such as the limb-girdle muscular dystro-
phies (LGMD), Becker muscular dystrophy, or metabolic
myopathies. [4] Our first objective was to optimize fu-
ture diagnosis in this patient group by classifying their
specific clinical features, and by delineating the distribu-
tion and severity of muscle weakness and the sequential
involvement of individual muscle groups during the
course of the disease.
Since 2006, enzyme replacement therapy (ERT) with re-
combinant human acid α-glucosidase has been approved
for the treatment of Pompe disease. In infants, treatment
generally improves cardiorespiratory function and motor
function, and prolongs survival. [5-8] In older children
and adults ERT was shown to improve or stabilize skeletal
muscle strength, muscle function and respiratory function.
However, the magnitude of the therapeutic response varies
between individual patients. [9-14] To fully assess the
effects of enzyme therapy, and to decide whom to treat
and when to start treatment, it is necessary to be optimally
informed about the course of disease prior to treatment,
and about factors influencing disease progression. We
thus prospectively studied the natural disease course, and
aimed to identify prognostic factors for faster disease pro-
gression and poor outcome in a large cohort of adult
Pompe patients.
Methods
Participants and study design
We performed a single-center, prospective, cohort study,
in which participation was open to all adults diagnosed
with Pompe disease who had not yet received treatment
with enzyme replacement therapy. Their diagnosis was
confirmed by acid α-glucosidase assay in leukocytes or
fibroblasts and by mutation analysis. All patients were
seen between October 2004 and August 2009 at Erasmus
MC University Medical Center, the designated center of
expertise for Pompe disease in the Netherlands. The
interval between visits was three to six months. Patients
were recruited either through neuromuscular centers
in the Netherlands and Belgium, through the Dutch
neuromuscular patient organization, or were referred to
our Center by their treating physicians. The researchprotocol was approved by the Central Committee on
Research Involving Human Subjects in the Netherlands
(CCMO). All patients provided written informed
consent.
Seven patients participated in the placebo arm of the
randomized, placebo controlled trial on the safety and ef-
ficacy of alglucosidase alfa in late-onset Pompe disease.
[13] Data on these patients collected during this period
are included in the present analyses. We have previously
reported long-term retrospective data on muscle strength
and pulmonary function in 16 patients with Pompe dis-
ease. [15] While 12 of these patients participated in the
current study, the present analyses were based solely on
new, prospectively obtained data.Procedures
We gathered information on the following: 1) the nature
of first symptoms and the age at which these had pre-
sented; 2) the age at which the diagnosis had been made;
3) duration of disease since onset of first symptoms; 4)
the presence of specific clinical features such as scoliosis,
bulbar involvement (defined as weakness of muscles
involved in speech, chewing and swallowing), winging of
the scapula (defined as a clearly visible protrusion of the
scapula when the patient was in a resting position or
was lifting the arms anteriorly or sidewards), muscle
atrophy, or ptosis; 5) the use of a wheelchair or walking
aids; 6) skeletal muscle strength; 7) the use of mechan-
ical ventilatory support; 8) the number of hours of
ventilatory support per day; 9) pulmonary function;
10) cardiac function; 11) acid α-glucosidase activity in
leukocytes and fibroblasts; 12) serum creatine kinase
(CK); and 13) type of GAA mutation.Skeletal muscle strength and muscle function
By manual muscle testing using the Medical Research
Council (MRC) grading scale [16] (range 0–5; all
patients were examined by NvdB or JdV), we measured
25 different muscle groups throughout the body to
define the distribution of skeletal muscle weakness and
the severity of involvement of the separate muscle
groups. We calculated a sumscore (range 0–130) for
the muscle groups that were involved most: neck
extensors, neck flexors, and bilateral shoulder adduc-
tors, shoulder abductors, shoulder exorotators, shoulder
endorotators, elbow flexors, elbow extensors, hip exten-
sors, hip flexors, hip abductors, hip adductors, knee
flexors and knee extensors. This score was subsequently
converted to a percentage of the maximum possible
score. Although the abdominal muscles and trunk mus-
cles were frequently involved, we did not include these
muscle groups in the MRC sumscore since they were
difficult to grade.
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Groningen, the Netherlands) was used as a second
measure of muscle strength to examine the following
muscle groups: neck extensors, neck flexors and bilateral
shoulder abductors, elbow flexors, elbow extensors, hip
flexors, hip abductors, knee flexors and knee extensors.
The value (Newton) measured in each muscle group was
expressed as a percentage of the median strength of
healthy females and males [17], and then combined into
a sumscore by averaging these for all 16 muscle groups,
producing a score between 0 and 100 percent.
Muscle function was assessed using the Quick Motor
Function Test (QMFT). [18] A total score (range 0–64)
was obtained by adding the scores of all items. This was
then expressed as a percentage of the maximum score.
Pulmonary function
Forced vital capacity (FVC) was measured using a Lilly type
pneumograph (Viasys Healthcare, Würzburg, Germany)
or the KoKo spirometry system (Ferraris Respiratory,
Louisville, USA) with the patient in upright seated and
supine positions, according to ATS/ERS standards. [19]
Results were expressed as a percentage of predicted normal
values. [20] A measured value below 80% of the predicted
value was considered to be abnormally low. Seven male
patients who were invasively ventilated were artificially
allotted a FVC value of 10% – just below the least observed
value – since their omission might have led to biased
results. These seven patients were however excluded from
the longitudinal analysis.
Statistical analysis
Baseline characteristics are summarized using descrip-
tive statistics. Differences between males and females,
and between patients with and without scapular winging,
were assessed using χ2 tests (wheelchair use, use of
mechanical ventilation, and presence of scoliosis, bulbar
muscle weakness, scapular winging or ptosis) or Mann–
Whitney tests (strength of individual muscle groups,
MRC sumscore, HHD sumscore, QMFT sumscore, and
FVC measured in sitting and supine positions). We used
the Spearman’s rank correlation coefficient (ρ) to calcu-
late the relationships between residual enzyme activity
and rate of decline in muscle strength and pulmonary
function, and between serum CK activity and age,
muscle atrophy and disease duration. Longitudinal ana-
lysis of muscle strength and pulmonary function was
performed using repeated measures ANOVA (random
coefficient models). The annual changes are expressed in
absolute percentage points (pp/y). For subgroup ana-
lyses, patients were divided into groups on the basis of
gender (male, female); wheelchair use (yes, no); use of
mechanical ventilation (yes, no); age at first study visit
(<50 or ≥50 years; taking the median as the cut-offpoint); disease duration (<15 or ≥15 years; taking the
median as the cut-off point); MRC/HHD sumscore at
study entry (categorization in tertiles); and FVC in sit-
ting position at study entry (<80 or ≥80% predicted).
Analyses were performed with SPSS for Windows (ver-
sion 15, SPSS Inc., Chicago, IL) or SAS (version 9.1, SAS
Institute Inc., Cary, NC). A p-value of ≤0.05 was consid-
ered statistically significant.
Results
Study population
In order of referral, we included 91 adult Pompe patients
from the Netherlands – representing virtually all known
patients in the Netherlands – and three patients from
Belgium. On average, there was a seven-year delay
between the first noted symptoms of Pompe disease and
the actual diagnosis. The characteristics of the study
population are summarized in Table 1.
Baseline measurements
Characteristic clinical features
A substantial number of patients had less familiar fea-
tures of Pompe disease, such as bulbar muscle weakness
(28%), prominent scapular winging (33%, Figure 1b), or
ptosis – not accompanied by external eye-movement
disturbances (23%; Figure 1c). Seventy-one percent of
patients with scapular winging had bulbar muscle weak-
ness, against 37% without scapular winging (p=0.001).
Clinical distribution and severity of muscle weakness, and
sequence of muscle involvement during the disease course
Shoulder abductors, abdominal muscles, paraspinal mus-
cles, hip flexors, hip extensors, hip adductors, and hip
abductors were affected in more than 80% of all patients
(Figure 2a). The strength of the quadriceps muscle was
reduced in only 55% of patients. The muscles of the
hands and feet were relatively spared, being affected in
under 10% of patients. Abdominal muscles, paraspinal
muscles – with exception of the neck extensors and
neck flexors –, hip flexors, hip extensors, hip adductors
and hip abductors were the most severely affected mus-
cles (Figure 2b). The pattern of muscle weakness was
symmetrical in 95% of patients, and the distribution of
weakness did not differ between males and females.
Relative to patients without scapular winging, patients
with scapular winging had more severe involvement of
the shoulder girdle musculature (trapezius muscle, del-
toid muscle, pectoral muscle, shoulder exorotators, and
shoulder endorotators; all p<0.02). The ‘limb-girdle’ and
trunk muscles were affected early in the course of the
disease, while the distal muscle groups – if they were
involved at all – were affected late in the course of the
disease (Figure 2c).
Table 1 Characteristics of the study population (n=94) a
General characteristics
Gender (males) 48 (51%)
Age at first study visit (years) 51.1 (38.3-60.6)
Age at onset of symptoms (years) 32.0 (25.5-40.0)
• < 18 years 10 (11%)
• ≥ 18 years 84 (89%)
Age at diagnosis (years) 40.2 (32.7-50.2)
Disease duration since onset of first symptoms
at first study visit (years)
15.3 (7.7-24.7)
Time since diagnosis at first study visit (years) 9.2 (0.6-16.0)
• 0 to 5 years 41 (44%)
• 5 to 10 years 15 (16%)
• 10 to 15 years 10 (11%)
• > 15 years 28 (30%)
Use of walking aids 14 (15%)
Wheelchair use 30 (32%)
Age at start of wheelchair use (years) 49.0 (43–56)
Use of mechanical ventilation b 27 (29%)
Age at start of mechanical ventilation (years) 48 (38.5-57.5)
First symptoms noted c
Skeletal muscle weakness 93 (99%)
• Difficulty running 30 (32%)
• Difficulty performing sports 22 (23%)
• Difficulty climbing stairs 24 (26%)
• Difficulty walking 15 (16%)
• Difficulty rising from an armchair 11 (12%)
• Difficulty rising from a lying position 9 (10%)
Fatigue 17 (18%)
Muscle soreness / cramps 16 (17%)
Respiratory failure 1 (1%)
Clinical features
Ptosis 22 (23%)
Bulbar muscle weakness d 26 (28%)
Scapular winging d 31 (33%)
Scoliosis 22 (23%)
Increased lumbar lordosis 62 (66%)
Prominent muscle atrophy 53 (56%)
• Shoulder girdle / upper arms 25 (27%)
• Trunk muscles 27 (29%)
• Pelvic girdle / Upper leg (Figure 1a) 40 (43%)
Laboratory parameters
CK (U/l)
• Males 449 (279–1040)
• Females 493 (237–715)
α-glucosidase activity in leukocytes
(nmol glucose/h/mg protein) e
1.2 (0.4-2.2)
α-glucosidase activity in fibroblasts
(nmol 4-MU/h/mg protein) f
13.0 (11.0-15.0)
Table 1 Characteristics of the study population (n=94) a
(Continued)
Genotype
• c.-32-13T>G / very severe or potentially
less severe pathogenic mutation
92 (98%)
• c.671G>A / c.525del 1 (1%)
• unknown 1(1%)
4-MU: 4-methylumbelliferyl-α-D-glucopyranoside.
a Data are number (%) or median (IQR). b More men then women used
mechanical ventilation (p=0.009). c Two or more complaints were counted if
these occurred within the same year. d More men than women had scapular
winging and bulbar muscle weakness (p=0.001 and p=0.05). e control range 48
to 215 nmol glucose/h/mg protein. f control range 45 to 180 nmol 4-MU/h/mg
protein.
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In a subset of 51 patients cardiac evaluation was per-
formed, comprising electrocardiography, Holter moni-
toring, two-dimensional echocardiography, low-dose
dobutamine stress echocardiography, and tissue Doppler
imaging. One patient had a mild hypertrophic cardiomy-
opathy, while four other patients had minor cardiac ab-
normalities that could be attributed to advanced age,
hypertension or preexisting cardiac pathology unrelated
to Pompe disease [21,22].
Laboratory parameters
Most patients had moderately increased serum CK; in two
patients it was more than 10 times the upper limit of nor-
mal, while 10 had a normal serum CK. Serum CK activity
was moderately inversely associated with age (ρ=−0.71,
p<0.001), disease duration (ρ=−0.45, p<0.001), and the
presence of muscle atrophy (ρ=−0.53, p<0.001).
Prospective follow-up
General aspects
Prospective follow-up data for a period longer than six
months were available for 66 patients (median 1.6 years,
range 0.5-4.2 years), 52 of whom were followed for longer
than one year, and 22 of whom for longer than two years.
Within the follow-up period, one patient became wheelchair
bound, mechanical ventilation was initiated in four patients,
and eight patients needed to increase their number of hours
of ventilation per day. One severely affected patient died
due to pneumonia complicated by respiratory failure.
Disease progression and predictors for disease outcome
Muscle strength and muscle function At baseline, the
MRC sumscore ranged from 39.2% to 100% (median
84.7%, one patient had the maximum possible score).
During follow-up, the MRC sumscore deteriorated by
1.3% points per year on average (p<0.001; Figure 3a).
Baseline values for hand-held dynamometry ranged from
31.6% to 100% (median 77.0%, three patients had the
maximum score). Within the observed follow-up period,
Figure 1 Clinical features in Pompe disease. Atrophy of the quadriceps muscle (A), scapular winging (B), and ptosis (C) as notable clinical
features in adults with Pompe disease. Photographs are printed with permission of the patients.
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(p<0.001; Figure 3b). With regard to the individual
muscle groups, strength declined significantly in the
elbow flexors, hip abductors, knee extensors and knee
flexors, ranging from -6.9 pp/y in elbow flexors to -2.5
pp/y in knee extensors (Figure 4). Subgroup analysis
(Table 2) revealed that the decline was faster in patients
with a reduced pulmonary function at baseline (FVC
<80%) than in those with normal pulmonary function
(−2.2 pp/y against −0.6 pp/y for MRC sumscore
(p=0.01), and −4.5 pp/y against −1.4 pp/y for HHD sum-
score (p<0.01)), and in patients who had had the disease
for longer than 15 years compared to those who had
been ill less long (−2.1 pp/y against −0.7pp/y for MRC
sumscore (p=0.04), and −4.2 pp/y against −2.0 pp/y for
HHD sumscore (p<0.01)). Baseline QMFT scores ranged
from 16.7% to 100% (median 63.7%). The changes that
were found in muscle strength were however not
reflected in changes in the QMFT (annual change
0.05% points, p=0.9). In no subgroups was a significant
decline observed.
Pulmonary function At baseline, FVC measured in sit-
ting position was reduced (<80% of the predicted value) in
56 patients (60%). The reduction in FVC was more prom-
inent in males than in females (mean FVC 57.5%predicted against 80.3% predicted, p<0.001). Patients
with scapular winging had significantly lower FVC than
those without scapular winging (mean FVC 50.7%
predicted against 84.5% predicted, p<0.001). In supine
position, 76 patients (80%) had a reduced FVC. Chan-
ging from a sitting to a supine position, FVC fell in 21
patients by over 25%, indicating possible diaphragmatic
weakness. Neither was testing in the supine position
attempted in 12 patients whose pulmonary function
was already severely restricted in sitting position. We
have recently reported more detailed data on pulmonary
function in some of the study cohort. [23] The mean
yearly change in FVC measured in supine position was
1.3% points (p=0.02), and for FVC in upright position
−1.0% points (p=0.06)(Figure 5). The rate at which
pulmonary function declined was consistent across
subgroups. There was no significant association between
the change in muscle strength or pulmonary function
and residual enzyme activity (Spearman’s rho for
MRC sumscore −0.21, p=0.14; for HHD sumscore
−0.51, p=0.74; for FVC in upright position 0.07, p=0.65;
and for FVC in supine position −0.32, p=0.84).
Disease course variability
In 59 patients progress of muscle weakness and pulmon-
ary dysfunction could be compared. In nine patients
Figure 2 Muscle weakness in adults with Pompe disease.
Distribution of skeletal muscle weakness (A), severity of muscle
weakness of the individual muscle groups (B), and involvement of
the individual muscles over time (C) in 94 adults with Pompe
disease.
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muscle strength did not decline during the prospective
follow-up period. Relative to the total group, they had a
shorter disease duration from onset of symptoms (7.3
years against 15.5 years, p=0.03). At baseline, the follow-
ing had all been higher, though not significantly: FVC in
sitting position (88.1% against 78.6%); FVC in supine
position (80.4% against 61.1%); MRC sumscore (87.2%
against 83.4%); and HHD sumscore (86.2% against
76.3%). In 28 patients (47%), pulmonary function and
skeletal muscle strength declined at a similar rate. In 22
patients (37%) the course of pulmonary function and
muscle weakness followed different courses, one deteri-
orating while the other remained stable, or one deterior-
ating faster than the other. Of the 50 patients who
deteriorated during the follow-up period, eight (2 males,
6 females) had a relatively fast decline – more than 5
percentage points per year – in muscle strength, while a
rapid decline in pulmonary function was seen in five
patients (1 male, 4 females). There were no significant
differences between these groups with regard to sex, age,
age at onset of symptoms, duration of disease, length of
prospective follow-up, level of residual enzyme activity,
and the severity of pulmonary or skeletal muscle in-
volvement at the start of the study.
Discussion
Characteristic clinical features and pattern of
muscle weakness
Our study in 94 adults with Pompe disease – which
included virtually all known adult patients in the Nether-
lands – shows that, generally speaking, muscle weakness
typically fits a pattern of limb-girdle myopathy. Interest-
ingly, our findings about the distribution of muscle weak-
ness, based on clinical examinations, match those of CT
and MRI studies. [24-26] We found weakness of the quad-
riceps muscle in 55% of patients only. This may have been
due to our method of measuring muscle strength: whereas
the advantage of the MRC score and HHD lie in the fact
that they are easy for the clinician to use, quantitative
muscle testing using QMT [13,27] may be more reliable
in patients with only minor loss of strength.
Besides limb-girdle weakness, many patients had less
familiar features, which are sometimes symptomatic of
other neuromuscular diseases. Though ptosis has been
reported in the literature in no more than seven adult
patients to date [28-31], it was found in almost one
quarter of our patients. Notably, while one might expect
AB
Figure 3 Longitudinal changes in muscle strength. Rate of disease progression measured by manual muscle testing (MRC sumscore) (A) and
hand-held dynamometry (HHD sumscore) (B) related to follow-up duration measured from time of inclusion in the study for 66 adults with
Pompe disease. The figure shows the measured values and regression lines at group level for the following subgroups: 1) Patients with
normal pulmonary function (FVC ≥80% predicted) and disease duration <15 years (circles, black line); 2) patients with normal pulmonary
function (FVC ≥80% predicted) and disease duration ≥ 15 years (red squares, red line); 3) patients with abnormal pulmonary function (FVC <80%
predicted) and disease duration <15 years (green triangles, green line); and 4) patients with abnormal pulmonary function (FVC <80%
predicted) and disease duration ≥ 15 years (blue asterisks, blue line).
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AB
Figure 4 Muscle strength in individual muscle groups measured by hand-held dynamometry. Values for individual patients are shown at
baseline (black squares) and during follow-up (last measured value) (open squares). Mean and standard error of the mean are given for each
muscle group.
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thirds of our patients.
Despite the fact that bulbar muscle weakness is
reported only occasionally in adult Pompe patients
[28,32], twenty-eight percent of the patients in our co-
hort had distinct bulbar muscle weakness. These patients
are at risk of pulmonary complications.
One third of patients had prominent scapular winging,
which is in line with several recent reports [32,33]. Many
of these patients also had bulbar muscle involvementand severer weakness of the shoulder-girdle muscles
than patients without scapular winging; these features
are reminiscent of FSHD. If patients with such a
“pseudo-FSHD” phenotype are overlooked, diagnosis
may be delayed. However, the asymmetrical distribution
of muscle weakness, the relatively common involvement
of the distal muscles of the lower limbs, and the absence
of severe or relatively severe pulmonary involvement in
FSHD will generally allow the two diseases to be diag-
nosed correctly [34].
Table 2 Disease progression in 66 adults with Pompe disease: annual changes in muscle strength and pulmonary function across various subgroups
MRC sumscore HHD sumscore QMFT score FVC sitting position FVC supine position
Total group n Annual
change
(%/year)
95% CI n Annual
change
(%/year)
95% CI n Annual
change
(%/year)
95% CI n Annual
change
(%/year)
95% CI n Annual
change
(%/year)
95% CI
65 −1.30 −1.95 to −0.66 55 −2.6 −3.72 to −1.45 62 0.05 −0.76 to 0.86 59 −1.04 −2.14 to 0.06 54 −1.30 −2.42 to −0.19
Subgroups n Annual
change
(%/year)
n Annual
change
(%/year)
n Annual
change
(%/year)
n Annual
change
(%/year)
n Annual
change
(%/year)
Gender
• Female 36 −1.41 31 −2.97 37 −0.22 36 −1.38 33 −2.27
• Male 29 −1.08 24 −1.99 25 0.57 23 −0.45 21 0.35
Age at study entry a
• < 50 years 34 −1.39 31 −2.06 33 −0.17 33 −1.34 31 −2.22
• ≥ 50 years 31 −1.21 24 −3.29 29 0.30 26 −0.69 23 −0.08
Disease duration at study entry a
• < 15 years 34 −0.70c 31 −1.95e 34 −0.07 35 −1.36 33 −1.37
• ≥ 15 years 31 −2.09c 24 −4.18e 28 0.17 24 −0.60 21 −1.16
FVC (sitting) at study entry
• ≥ 80%
predicted
33 −0.62d 32 −1.43f 33 −0.21 33 −1.09 31 −1.59
• < 80%
predicted
32 −2.21d 23 −4.52f 29 0.31 26 −0.89 23 −0.92
Ventilation at study entry
• No 49 −1.12 46 −2.50 50 0.24 50 −1.30 47 −1.50
• Yes 16 −1.83 9 −3.55 12 −0.70 9 1.07 7 0.32
Wheelchair use at study entry
• No 47 −0.94 44 −2.28 47 −0.39 47 −0.98 43 −0.99
• Yes 18 −2.36 11 −3.92 15 1.44 12 −1.22 11 −2.57
MRC / HHD sum score at study entry b
• < 33rd
percentile
18 −1.27 10 −2.06 20 0.49 12 −0.30 9 −1.59
• 33rd to 66th
percentile
23 −1.31 22 −4.34 23 −0.06 23 −2.40 21 −2.01
• ≥ 66th
percentile
24 −0.98 23 −1.56 19 −0.41 24 −0.34 24 −0.63
MRC: Medical Research Council; HHD: Hand-Held Dynamometry; QMFT: Quick Motor Function Test; FVC: Forced Vital Capacity; CI: confidence interval. a the median was taken as the cut-off point. b categorization in
tertiles. n represents the number of patients for whom data were available for each specific measurement. For muscle strength, no sumscore was calculated if measurements for three or more individual muscle groups
were missing (e.g. due to severity of muscle weakness or injury). For seven invasively ventilated patients no reliable measurements of FVC could be performed. Neither could testing in the supine position be endured
by 5 patients whose pulmonary function was already severely restricted in sitting position.
Data shown are mean annual changes (percentage points per year) as calculated by repeated measures ANOVA. For MRC sumscore and HHD sumscore there were significant differences between groups based on
disease duration and FVC at study entry: c) p=0.04, d) p=0.01, e) p<0.01, and f) p<0.01.
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AB
Figure 5 Longitudinal changes in pulmonary function. Decline in pulmonary function in the upright seated (A) and supine (B) positions
related to follow-up duration. Circles represent the measured values, the line represents the mean regression line at a group level.
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ing that a normal serum CK does not rule out Pompe
disease [35-37]. In early stages of the disease, however,
normal serum CK is quite uncommon. Although we did
not systematically perform electromyography or musclebiopsies, it is well known that these may reveal no or
only non-specific abnormalities in a considerable num-
ber of patients [38,39]. Therefore, measurement of acid
α-glucosidase activity and mutation analysis remain es-
sential to confirm the diagnosis.
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Although the average follow-up duration of 19 months
seems rather short for a chronic disorder such as Pompe
disease, it is the longest prospective follow-up ever car-
ried out in “late-onset” Pompe disease. Moreover, as
many patients are now treated with enzyme replacement
therapy, prospective data on the natural course of the
disease over a longer period of time are now impossible
to obtain.
We found a significant worsening of muscle strength,
reflected by declines in MRC sumscore (mean decline
−1.3% pp/y) and HHD sumscore (mean decline −2.6%
pp/y). Although we found significant changes in muscle
strength and some patients became wheelchair or venti-
lator dependent during follow-up, the QMFT did not in-
dicate a deterioration in limb-girdle muscle function.
There may be two main reasons for this. First, the de-
cline in muscle strength may have been too small to
cause changes in functional daily activities within the
observed time-span. Second, although the QMFT
showed a good discriminative ability and good respon-
siveness to change after start of enzyme replacement
therapy, it may not be sensitive enough to reflect minor
changes in strength in functional changes during the
natural course [18].
Mechanical ventilation became necessary in four of
the 67 hitherto un-ventilated patients, eight patients
needed to increase their number of hours of ventilation,
and one patient died due to respiratory complications.
Despite this indication that pulmonary function clearly
worsened during the time-span of the study, our findings
regarding the yearly decline seem somewhat lower than
those of other studies. [13,27] This may have been due
to our method of patient selection: in the present study
participation was open to all adult patients with a con-
firmed diagnosis of Pompe disease, including those with
very limited pulmonary function who were invasively
ventilated 24 hours a day. Although this reflects the
spectrum of disease encountered in daily practice, one
would expect further deterioration of pulmonary func-
tion in these patients to be minimal, thereby partly ob-
scuring decline in the total group. Secondly, when
enzyme replacement therapy became commercially
available, we decided first to treat the most severely
affected patients and patients with a rapid decline in
pulmonary function and muscle strength, while patients
with a slow disease course were started on ERT at a later
stage. As a result, the length of prospective follow-up for
the most severely affected patients was somewhat
shorter (1.1 years on average) than for the least affected
patients (1.7 years on average, the longest follow-up
being 4.2 years). Another factor that could have influ-
enced the estimated rate of decline is the fact that data
on seven patients who participated in the placebo arm ofthe randomized controlled trial on the safety and efficacy
of alglucosidase alfa in late-onset Pompe disease were
included in the present analyses. However, a second ana-
lysis, excluding these patients to overcome a possible
placebo effect, led to similar estimates of the rate at
which muscle weakness and pulmonary dysfunction pro-
gress (not shown).
It should be noted that all patients except one had the
c.-32-13T>G (IVS1-13T>G) mutation in combination
with a null allele. Although this is the most common
genotype in adult Pompe patients – present in 68-93%
of patients [27,40,41] – the estimated rate of disease
progression may not apply to patients with different
genotypes.
Predictors for disease outcome and disease
course variability
Longer disease duration (≥ 15 years) and pulmonary dys-
function (FVC <80%) were shown to be associated with
a faster decline in muscle strength. Our results thus sup-
port those of the only other prospective study in adult
Pompe patients, which found baseline status and dur-
ation of illness to be the most important predictors of
disease severity and disease progress [27].
A subset of patients with shorter average disease dur-
ation and better baseline status did not deteriorate dur-
ing follow-up, indicating that there might be a stable
phase of several years before a gradual decline inevitably
occurs. This raises an interesting dilemma regarding the
best time to start ERT. [42] On the one hand, in patients
who are only mildly affected and whose condition is
stable, one might advocate that this – costly – lifelong
treatment be postponed. On the other hand, studies
measuring the effect of ERT show a trend toward better
outcome in patients who were in a relatively good condi-
tion at the start of treatment. [11,13,14] On the basis of
our results, we suggest to start ERT in all patients with
pulmonary dysfunction and in patients with progressive
muscle weakness, whereas in patients with minimal
weakness, or in patients with solely elevated laboratory
parameters treatment may be postponed, provided that
they are monitored regularly. At our center, all patients
undergo evaluation of muscle strength, pulmonary func-
tion, cardiac function, and hearing at referral, and evalu-
ation of progression of muscle weakness and pulmonary
dysfunction every three months thereafter.
Conclusions
In summary, since the approval of enzyme replacement
therapy in Pompe disease, early recognition of affected
individuals has gained importance. The typical limb-
girdle type muscle weakness – including prominent in-
volvement of the trunk musculature – combined with
early and disproportionate pulmonary involvement
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http://www.ojrd.com/content/7/1/88relative to the degree of skeletal muscle weakness should
raise the suspicion of Pompe disease. Although these are
the most salient characteristics, less familiar features
such as ptosis, scapular winging and bulbar weakness
are far more common than generally thought. If these
are recognized properly, timely diagnosis will be facili-
tated. Longer disease duration and reduced pulmonary
function stand out as the most important factors for a
rapid decline in muscle strength, which may aid in de-
ciding whom to treat and when.
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